share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  08/12 12:06
Moomoo AI 已提取核心訊息
60 Degrees Pharmaceuticals, Inc., a pharmaceutical company specializing in infectious disease treatments, has announced the completion of a 1-for-12 reverse stock split of its common stock, effective August 12, 2024. The reverse stock split was approved by the company's stockholders on July 16, 2024, and the final ratio was determined by the Board of Directors on July 19, 2024. The split, which was filed with the Secretary of State of Delaware on July 30, 2024, is intended to comply with Nasdaq's minimum bid price requirement. The company's common stock will continue trading on the Nasdaq under the symbol 'SXTP' with a new CUSIP number. No fractional shares were issued; instead, fractional amounts were rounded up to the nearest whole share. The reverse stock split affects all stockholders uniformly and does not change their percentage equity interest in the company. Equity Stock Transfer, LLC will act as the agent for the reverse stock split, and stockholders do not need to take any action to receive post-split shares.
60 Degrees Pharmaceuticals, Inc., a pharmaceutical company specializing in infectious disease treatments, has announced the completion of a 1-for-12 reverse stock split of its common stock, effective August 12, 2024. The reverse stock split was approved by the company's stockholders on July 16, 2024, and the final ratio was determined by the Board of Directors on July 19, 2024. The split, which was filed with the Secretary of State of Delaware on July 30, 2024, is intended to comply with Nasdaq's minimum bid price requirement. The company's common stock will continue trading on the Nasdaq under the symbol 'SXTP' with a new CUSIP number. No fractional shares were issued; instead, fractional amounts were rounded up to the nearest whole share. The reverse stock split affects all stockholders uniformly and does not change their percentage equity interest in the company. Equity Stock Transfer, LLC will act as the agent for the reverse stock split, and stockholders do not need to take any action to receive post-split shares.
製藥公司60 Degrees Pharmaceuticals, Inc.專門從事傳染病治療，於2024年8月12日宣佈完成一項1股合12股的股票拆分。該反向拆分於2024年7月16日獲得公司股東批准，並於2024年7月19日由董事會確定最終比例。該拆分已在2024年7月30日向特拉華州國務卿提交，並旨在符合納斯達克對最低出價的要求。該公司的普通股將繼續在納斯達克交易，交易標的爲「SXTP」，並採用新的CUSIP編號。不發行碎股，而是將少於1股的股份四捨五入取整。該反向拆分對所有股東均勻生效，不會改變其在公司中的股權比例。股權轉讓公司將充當反向拆分的代理，股東無需採取任何行動即可獲得拆分後的股份。
製藥公司60 Degrees Pharmaceuticals, Inc.專門從事傳染病治療，於2024年8月12日宣佈完成一項1股合12股的股票拆分。該反向拆分於2024年7月16日獲得公司股東批准，並於2024年7月19日由董事會確定最終比例。該拆分已在2024年7月30日向特拉華州國務卿提交，並旨在符合納斯達克對最低出價的要求。該公司的普通股將繼續在納斯達克交易，交易標的爲「SXTP」，並採用新的CUSIP編號。不發行碎股，而是將少於1股的股份四捨五入取整。該反向拆分對所有股東均勻生效，不會改變其在公司中的股權比例。股權轉讓公司將充當反向拆分的代理，股東無需採取任何行動即可獲得拆分後的股份。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息